赛托姆X的Varseta-M在晚期结直肠癌中显示出有希望的反应率和安全性,计划在2026年中期召开FDA会议. CytomX's Varseta-M showed promising response rates and safety in late-stage colorectal cancer, with plans for an FDA meeting mid-2026.

CytomX治疗学报告了第1阶段的以下数据:EpCAM针对晚线转移性直肠癌的Varseta-M抗体-药物结合,显示在10毫克/千克和8.6毫克/千克时分别有32%的客观反应率和20%的客观反应率,中位无进展性存活率分别为7.1个月和6.8个月。 CytomX Therapeutics reported Phase 1 data for its EpCAM-targeting antibody-drug conjugate Varseta-M in late-line metastatic colorectal cancer, showing a 32% objective response rate at 10 mg/kg and 20% at 8.6 mg/kg, with median progression-free survival of 7.1 and 6.8 months, respectively. 该药物展示了可管理的安全状况,没有剂量限制毒性,通过预防减少了严重腹泻,并保持了高浓度的EpCAM表达方式。 The drug demonstrated a manageable safety profile with no dose-limiting toxicities, reduced severe diarrhea through prophylaxis, and maintained high EpCAM expression. 该公司计划在2026年中期召开美国FDA会议,讨论注册试验,并预计到年底将进行组合研究和新的试验. The company plans a U.S. FDA meeting mid-2026 to discuss a registrational trial, with combination studies and new trials expected by year-end.